Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, 18 October 2023-9 March 2024.
Estimated Burden of COVID-19 Illnesses, Medical Visits, Hospitalizations, and Deaths in the US From October 2022 to September 2024.
COVID-19 Antiviral Treatment: Examining Knowledge, Access, Trust in Sources of Information and Willingness to Use Among Essential Workers: A Cross-Sectional Survey of Cohort Participants.
Does Home COVID-19 Testing Bias COVID-19 Vaccine Effectiveness Estimates?
Post-MIS-C cardiovascular outcomes: a systematic review.
Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus.
Effectiveness of COVID-19 Vaccines by Genetic Match to Circulating SARS-CoV-2 Strains in the United States, 2023–2025
Characterizing Oseltamivir Use among Community-Dwelling Patients Diagnosed with Influenza Virus Infection, 2023-2025
Estimating influenza transmission parameters: Comparing two study designs, 2023–2024
Influenza vaccine effectiveness against influenza A-associated hospitalization and severe in-hospital outcomes among adults in the United States, 2024–2025
Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years - VISION and IVY Networks, September 2024-January 2025.
RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons
RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons.
Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses - IVY Network, September 1, 2022-March 30, 2023.
Pneumococcal Serotype Distribution and Coverage of Existing and Pipeline Pneumococcal Vaccines
Use of SGLT2i Versus DPP-4i as an Add-on Therapy and the Risk of PAD-Related Surgical Events (Amputation, Stent Placement, or Vascular Surgery): A Cohort Study in Veterans With Diabetes.
Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations, United States, 1 September 2023 to 31 May 2024
Influenza With and Without Oseltamivir Treatment and Neuropsychiatric Events Among Children and Adolescents.
Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations, United States, 1 September 2023 to 31 May 2024.
Fluorescent antibody-based detection and ultrastructural analysis of Streptococcus pneumoniae in human sputum.
Reduced risk of SARS-CoV-2 infection among household contacts with recent vaccination and past COVID-19 infection: results from 2 multisite case-ascertained household transmission studies.
Pneumococcal Serotype Distribution and Coverage of Existing and Pipeline Pneumococcal Vaccines.
Estimating the generation time for influenza transmission using household data in the United States.
Patient- and Community-Level Characteristics Associated With Respiratory Syncytial Virus Vaccination.
Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study.
Serious Neurologic Events With Seasonal Influenza in Young Children.
Pandemic Social Distancing and Declines in Nasopharyngeal Carriage of Pneumococcus and Related Antimicrobial-Resistant Genes: Evidence From Household-Based Cohort Studies in Lima, Peru.
Effectiveness of mRNA COVID-19 Vaccines and Hybrid Immunity in Preventing SARS-CoV-2 Infection and Symptomatic COVID-19 Among Adults in the United States.
Asymptomatic and Mildly Symptomatic Influenza Virus Infections by Season: Case-Ascertained Household Transmission Studies, United States, 2017-2023.
Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trial.